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Improving quality of life through the
routine use of the patient concerns
inventory for head and neck cancer
patients: a cluster preference randomized
controlled trial
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Abstract
Background: The consequences of treatment for Head and Neck cancer (HNC) patients has profound detrimental
impacts such as impaired QOL, emotional distress, delayed recovery and frequent use of healthcare. The aim of this trial is
to determine if the routine use of the Patients Concerns Inventory (PCI) package in review clinics during the first year
following treatment can improve overall quality of life, reduce the social-emotional impact of cancer and reduce levels of
distress. Furthermore, we aim to describe the economic costs and benefits of using the PCI.
Methods: This will be a cluster preference randomised control trial with consultants either ‘using’ or ‘not using’ the PCI
package at clinic. It will involve two centres Leeds and Liverpool. 416 eligible patients from at least 10 consultant
clusters are required to show a clinically meaningful difference in the primary outcome. The primary outcome is the
percentage of participants with less than good overall quality of life at the final one-year clinic as measured by the
University of Washington QOL questionnaire version 4 (UWQOLv4). Secondary outcomes at one-year are the mean
social-emotional subscale (UWQOLv4) score, Distress Thermometer (DT) score≥ 4, and key health economic measures
(QALY-EQ-5D-5 L; CSRI).
Discussion: This trial will provide knowledge on the effectiveness of a consultation intervention package based around
the PCI used at routine follow-up clinics following treatment of head and neck cancer with curative intent. If this
intervention is (cost) effective for patients, the next step will be to promote wider use of this approach as standard care
in clinical practice.
Trial registration: 32,382. Clinical Trials Identifier, NCT03086629. Protocol: Version 3.0, 1st July 2017.
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Background
The incidence of Head and neck cancer (HNC) is increasing,
the three main sites being oral cavity (mouth), oropharynx
(throat) and larynx (voice box) with about 11,000 new can-
cers in the UK each year http://www.cancerresearchuk.org/
about-cancer/mouth-cancer. Treatments such as surgery
and chemo-radiotherapy have a detrimental effect on basic
functions including speech, swallowing and appearance.
These in turn can have a profound negative influence on
emotional well-being and social integration http://www.han-
dle-on-qol.com/About.aspx. Patients often do not raise issues
of concern in their follow-up consultations and it can be a
challenge for clinicians to facilitate this in a busy clinic [1].
Questionnaire prompt lists (QPL) are a means to allow pa-
tients to raise their agenda and help focus consultations [2–
5]. The Patient Concerns Inventory (PCI-HN) is an item
prompt list specific to head and neck cancer [6] http://www.
headandneckcancer.co.uk/professionals/patient-concerns-in-
ventory, and differs from many QPLs, which are more gen-
eral cancer tools [7]. The PCI-HN was designed for routine
clinic consultations within the context of NHS financial con-
straints. It is freely available http://www.patient-concerns-in-
ventory.co.uk and is in the early phases of development for
other cancers and chronic conditions. The PCI consists of
56 clinical items, which patients select from before their ap-
pointment, to help guide the outpatient consultation through
the symptoms and problems that they may experience fol-
lowing their treatment for HNC. It helps to focus the con-
sultation, aid doctor-patient communication, and can assist
in signposting patients to other professional for advice and
support.
The PCI supports several national initiatives and is set in
the context of the national debate about how to bring about
more person-centred care [8, 9] and the National Cancer
Survivorship Initiative http://www.ncin.org.uk/cancer_type_
and_topic_specific_work/topic_specific_work/survivorship
which ‘aims to ensure that those living with and beyond
cancer get the care and support they need to lead as healthy
and active a life as possible, for as long as possible’. In a sur-
vey of the British Association of Head and Neck Oncology
Nurses (BAHNON), the PCI at that time, was the preferred
assessment and the majority (60%) felt, as a head and neck
specific tool, it was ‘most appropriate’ [10].
Oncology review clinics are busy and barriers such as
time constraints, a medical focus of the consultation,
and lack of level 1 evidence of patient benefit from the
use of the PCI, prevents its wider implementation. Al-
though pilot work has shown that patients completing
the PCI would like to continue to use it in clinic and
that it is feasible, [11, 12] clinicians tend to focus on
traditional medical aspects. There is evidence that con-
sultations can be improved through clinicians developing
skills in detecting and responding to patient distress,
thereby improving their patients’ emotional functioning
and reducing psychological distress [13, 14]. Preliminary
findings around the PCI suggest that its use in clinic al-
lows emotional issues to be discussed more openly - not-
ably fears of recurrence, anxiety and depression [15, 16].
Hence the PCI could help clinician communication with
patients in these important areas and consequently im-
pact on how consultations are constructed.
The PCI provides a process by which the patient has re-
peated opportunities to raise issues they feel are important
and that they want to discuss. It can be argued that the
routine repeated use of the PCI in follow-up clinics will
benefit patients wanting support to speak more openly
about problems or concerns e.g. psychosocial causes of
symptoms; need for psychosocial help; to seek explanation
and reassurance for more physical explanations about
their cancer and about the side-effects of treatment. It is
postulated that this will have a positive impact on quality
of life and emotional distress and be demonstrable by one
year following HNC treatment [17]. Thus far, the majority
of evidence related to the PCI-HN has been derived from
one clinic setting. By conducting a randomised controlled
trial (RCT) across multiple consultants, it will be possible
to rigorously evaluate if the repeated inclusion of the PCI-
HN in routine post-treatment consultations does make a
significant and clinically meaningfully difference in patient
reported quality of life and distress.
Methods/design
This is a preference cluster randomised control trial with
consultants either ‘using or ‘not using’ the PCI at clinic.
416 HNC eligible patients from at least 10 consultant
clusters are required to show a clinically meaningful dif-
ference in the primary outcome, that is having less than
good overall QOL at the final one-year clinic as mea-
sured by the relevant question on the UWQOL-v4 [18].
Before treatment, eligible patients will be asked to con-
sent to participation in the ‘research cohort’. Patients
agree to their clinical data being used (Table 1) and to
completing research questionnaires before each post-
treatment consultation, some of which might be used in
their consultation. Completion of all pre-consultation
questionnaires including the PCI items will be by com-
puter (desktop, tablet, IPAD). Quality Assurance is by ini-
tial training and later booster sessions for consultants and
a post consultation survey of those in the PCI arm. Also,
in the first six months of the study a random selection of
clinic consultations will be taped in order to check how
consultants do or do not use the PCI package.
A Steering Group is guiding the research and a joint-site
Management group will manage it. Each site will have
regular Project Team meetings to review progress. Day to
day management issues will be addressed with each unit
Lead Researcher. A data manager (based at Aintree R&D)
will have overall responsibility for ensuring data quality
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and integrity. The study will last three years comprising of
set-up and piloting, 12 months of recruitment, 15 months
of follow-up and analysis, and then write-up and initial
dissemination.
In analysis, the two patient groups will be compared after
adjusting for relevant case-mix and for effects of patients
being within consultant clusters. A summary flowchart of
the key features of this trial is shown as Fig. 1.
Purpose of the study and hypotheses
The main purpose of this three-year research project is
to investigate whether incorporating the PCI into rou-
tine head and neck cancer (HNC) follow-up consulta-
tions improves the overall QOL of patients. The Null
hypothesis is that there is no difference between trial
groups in the percentage of patients with less than good
overall QOL at one year following the first baseline rou-
tine clinic post-treatment.
Participant eligibility
Eligible patients will have a first occurrence of HNC,
and be treated curatively (all sites, stage of disease, treat-
ments). To ensure participation of patients with little or
no written or spoken English, translation services will be
provided as necessary.
Patients treated with palliative intent and patients with a
history of previous HNC or recurrence will be excluded
from the study. Although the PCI could benefit these pa-
tients the primary endpoint of this study is QOL at one
year. For reasons of engagement and ethics, patients with
a history of cognitive impairment, psychoses or dementia
are excluded, as discussed and identified at the staging/
treatment decision-making Multi-Professional Team
meeting (MDT). Patients who initially are included and
treated curatively but who later start receiving treatment
with palliative intent will no longer be asked to continue
their participation in the research.
Method of randomisation
Problems of consultant contamination (from switching
back and forth from using to not using the PCI package as
would be required with conventional randomisation) indi-
cate this should be a cluster RCT, in that consultants are
randomised to ‘using or ‘not using’ the PCI at all their trial
clinics. The steering group approved a randomisation
process incorporating consultant preference; a method re-
ported previously [19]. The aim is to limit the chance oc-
currence of PCI-sceptic consultants dominating the PCI
group and PCI-enthusiastic consultants the non-PCI
group. Those with a strong preference are offered their
preferred group and those with no preference are rando-
mised. The allocation process was overseen by the medical
statistician involved, before any patient recruitment oc-
curred. At Leeds, three of six consultants preferred to be
in the PCI group, while the other three consultants had
no preference as to group and were all allocated to the
non-PCI control group. At Liverpool, three of eight con-
sultants preferred to be in the non-PCI control group.
One of the other five consultants was randomly allocated
to the non-PCI control group, leaving four to be in the
PCI group. Thus, at the two sites, seven consultants were
in each arm of the trial.
Study intervention
Patient completion of the PCI and its inclusion into the
regular review clinic consultation within a summary paper
output is the ‘intervention’ and is compared to standard
out-patient follow-up. The pre-consultation question-
naires and PCI will be used from the first post-treatment
clinic (baseline) onwards for one year. The trial will only
apply for routine out-patient follow-ups. Completion of all
pre-consultation questionnaires and the PCI is by com-
puter (desktop, tablet, IPAD). Assistance (from trained
volunteers) will be available to patients as required. Pa-
tients of intervention consultants complete the PCI
throughout the trial while patients of control consultants
do not complete the PCI at all. All study patients will see
their consultant surgeon at 6–8 weekly intervals for
planned out-patient review. This might be as joint con-
sultation with the oncologist depending on the configur-
ation of the clinic.
Table 1 Schedule for collecting clinical and demographic
details
Timepoint Trial Period
Enrolment Baseline clinic Follow
up clinics
Gender X
DOB X
IMD 2015 X
Smoking and Drinking Details X Xa
Living Situation X
Employment X
Income X
Primary Diagnosis (ICD code) X
Tumour Site X
Treatment Plan X
Ethnicity X
TNM Stage X
Cancer Staging X
Histology (SNOMED) X
HPV Status X
Co-Morbidity X
ACE 27 X
aCompletion at patient 6 and 12 month study visit
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While waiting for each consultation the Intervention
group patients complete the following:
 Health related QOL (UW-QOLv4)
 EQ-5D-5 L
 Distress Thermometer (DT)
 PCI
Intervention patients then take a summary paper out-
put of their data into the clinic consultation (Fig. 2).
Post-consultation they will be asked to complete:
 Post-Consultation Patient Feedback about the use of
the PCI.
 Client Service Receipt Inventory (CSRI) at 6 and
12 months.
The post consultation data collection will involve self-
completion in clinic but either research assisted completion
or telephone completion is possible if the patient prefers.
Control patients will complete exactly the same informa-
tion as intervention patients apart from the PCI and the
post consultation feedback on the PCI. They do not take
any summary output with them into the consultation. The
summary output is a product of the raw inputted data from
the patient being run through a software programme that
indicates (1) all the items selected from the PCI that the pa-
tient wants to discuss (2) those domains from the UWQOL
Fig. 1 Patient Flow Diagram
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questionnaire for which the patient responses suggest a
significant problem or dysfunction (using software algo-
rithms derived from earlier work with the UWQOL [20],
(3) the patient’s overall QOL and (4) the Distress Therm-
ometer score. The presence of this summary output during
the consultation is the difference in reality between the
intervention and control groups as far as the interaction be-
tween consultant and patient is concerned.
Data collection and outcome measures
Unit Clinical Trials Nurses who recruit eligible patients
will keep recruitment and clinic attendance logs. The
dedicated funded Unit researchers will collect baseline
clinical/demographic data either via a baseline clinic
questionnaire, with demographic questions chosen as far
as possible to match those included in the head and
neck 5000 project [21], or by extraction from baseline
clinical records. Baseline data will include cancer site,
disease severity, HPV status, treatment details, gender,
age, deprivation [IMD from post code], smoking, alco-
hol, and ACE-27 comorbidity. All clinical outcome data
will be collected automatically via IPAD at each consult-
ation. A data manager (based at Aintree) will have over-
all responsibility for ensuring data quality and integrity.
Primary outcome measure
The primary outcome measure is overall QOL, specifically
the percentage with less than good overall QOL at the
final one-year clinic as measured by the single UWQOL-
v4 question [18]. The anticipated result in the control
group is 30%. The UW-QOLv4 is a commonly used HNC
specific HRQOL questionnaire [22, 23] and has been used
with HNC patients at the Aintree Regional Head and
Neck Unit since 1995. Over 1000 patients have completed
over 5000 UW-QOL questionnaires giving the research
team considerable experience in analysing and reporting
this QOL measure.
Secondary outcome measures
1. Mean social-emotional subscale score of UW-QOL
The Aintree Research team was involved in
developing the UW-QOL subscales, and the social-
emotional subscale [20] is the mean of 6 domain
scores (each 0–100) - anxiety, mood, pain, activity,
recreation and shoulder function. The anticipated
result in the control group is a mean score of 75.
2. Distress Thermometer (DT) score of 4 or more
(range 0 to 10). The anticipated result in the
control group is 34%. The Distress Thermometer
(DT) is a single item self-report measure and has
been used to screen for distress in various cancers
[24–27]. A score of four and above denotes
significant distress as this correlates with optimal
sensitivity and specificity to the Hospital Anxiety
Depression Scale [25, 28].
Cost-effectiveness
1. Quality-adjusted life year (QALY).
Quality-adjusted life year (QALY) is used as a
summary measure of health benefit for economic
evaluation, using the EQ-5D-5 L health index to ad-
just for patient QOL [29, 30]. QALY is used as a
common unit to allow comparisons across different
interventions or disease areas [31]. EQ-5D-5 L is a
validated generic, health-related, preference-based
measure comprising mobility, self-care, usual activ-
ities, pain and discomfort, anxiety and depression.
These are complemented by a visual analogue scale
(VAS) [32], on which patients are asked to indicate
their current health from 0 (worst imaginable
health) to 100 (best imaginable health) [33].
2. Health service use and costs
Health service use by participating patients will be
collected using a Client Service Receipt Inventory
(CSRI). CSRI is a form that is usually administered in
an interview setting or by self-completion via postal sur-
veys or at clinics – asking them to recall retrospectively
the type and frequency of their contacts with primary
and secondary care NHS services. A CSRI form adapted
to the study was developed using existing CSRIs, avail-
able from the DIRUM open access database http://
www.dirum.org, as a reference and guidance with input
from study researchers. For this trial, services such as
physiotherapist, occupational therapist, social worker
and others are included. To translate the service use
into costs, unit costs from published sources will be ap-
plied to the patients’ self-reported service use data and
the mean total cost of care per patient over 12 months
will be calculated in each group. CSRI is the most com-
mon means of collecting service use data, usually with a
short recall period of up to 6 months [34, 35], in health
economics studies that require data across a range of
health care settings. CSRIs were developed first in the
field of mental health economics [36], and a review of
their use is published by Ridyard and Hughes [37].
6. Cost of the PCI intervention
Resources and materials use for the delivery of the
PCI intervention will be recorded and costed and the
total cost of the PCI intervention will be calculated.
Sample size calculation
We have used nearly 20 years of accumulated experience
with the UW-QOL to estimate a sample size that is
Rogers et al. BMC Cancer  (2018) 18:444 Page 5 of 10
pragmatic enough for a trial to be doable, yet able to detect
meaningful differences if they exist. In regard to all
UWQOL records collected the percentages of patients
reporting less than good overall quality of life were rela-
tively similar over different time periods from diagnosis and
the expectation for the trial control group was taken as
30% after about 12 months. Cluster randomized trials re-
quire larger sample sizes than the individually randomised
design because observations on individuals in the same
cluster tend to be correlated, thereby reducing the effective
Fig. 2 Example of PCI printouts
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sample size. The degree of correlation within consultant
clusters, as estimated by the intra-class correlation (ICC)
was estimated as barely above zero (6.7e-05) for consultants
at Aintree. Assuming a likely control group outcome of
30%, an ICC value of 0.01 for the trial and not wishing to
miss a halving in outcome rate, then a total of 312 patients
from at least 10 consultants were required. After factoring
a likely loss of 15% through patient mortality during the
follow-up period and a possible maximum loss of 10% from
initial non-consent, this then implied a total of 416 eligible
patients needing to be approached for participation to the
research. This number would also detect a moderate-sized
clinical difference of 10 units (75 Vs. 85) in the mean com-
posite social-emotional subscale score, for which an ICC es-
timate of 0.025 was obtained for consultants within
Aintree. Data from an MD project with 325 HNC patients
at Aintree gave an estimated 34% with a Distress Therm-
ometer score ≥ 4, and the trial numbers would be sufficient
to detect a halving in this outcome.
Statistical analysis
As inference will target the individual patient level, ana-
lyses will need to adjust for potential clustering in the
data. We will report results for each group (PCI, non-PCI)
and the estimated effect size from the use of PCI and its
precision (95% confidence interval). For the primary out-
come, we will report the intra-cluster correlation coeffi-
cient to assess the amount of clustering. In reporting
results, we will follow the CONSORT statement extension
applicable to cluster RCTs. We will use random effects
(multi-level) logistic regression methods and will estimate
the effect of PCI after making adjustment for relevant
case-mix and for clustering effects of patients being within
consultant clusters. Only baseline patient factors will be
considered as case-mix adjusters and these include age,
gender, treatment, overall clinical stage, tumour site and
baseline clinic assessment of whether overall UWQOL
was less than good (Y/N). A P value ≤0.05 is considered
statistically significant. Secondary clinical outcomes will
be analysed as per protocol.
We will fully cost the delivery of the PCI intervention
and associated costs such as training and other materials
used. We will use published national average NHS refer-
ence consultant costs, accounting for overheads. From an
NHS perspective, we will undertake a primary cost-
effectiveness analysis of the PCI approach, using the change
in % of patients with ‘less than good’ overall QOL between
baseline and one-year as the outcome effect, and a subse-
quent cost-utility analysis using QALY as the outcome ef-
fect measured using the EQ-5D-5 L questionnaire. Costs of
service use and QALY data will be derived from the CSRI
and EQ-5D-5 L questionnaires collected at baseline, 3, 6, 9
and 12 months. The area under the curve method will be
used to calculate QALYs, weighting survival by QOL
weights obtained from the EQ-5D-5 L. We will compare
our findings with unofficial NICE thresholds (ceilings) of
£20,000 to £30,000 per QALY. Discounting is unnecessary
given the time period. We will account for patient cluster-
ing, producing cost-effectiveness planes and acceptability
curves (CEACs) to convey to policy makers the probability
that PCI approach is cost-effective at different payer thresh-
olds. We will undertake 5000 bootstrapped replications to
generate confidence intervals around point estimates. The
CSRI also allows us to account for the impact on healthcare
service use from intervention participation, important when
further rolling out the PCI approach.
Quality assurance (QA)
Quality Assurance will be ensured by initial training and
booster sessions for consultants, together with post con-
sultation patient feedback and audio taping of a number
of consultations.
Training
There will be a short training programme for staff using
the PCI before any patient recruitment. A brief manual/
instruction booklet is used to talk through how the PCI
should be used in consultations. There will also be two
refresher sessions at 4 and 8 months into the trial re-
cruitment phase.
Patients completing the PCI will be asked to complete
a post-consultation feedback on paper identified by
unique study number and date of clinic; they will be
asked to leave this in clinic with the research team; tele-
phone completion of this will also be available. The
question is: Did the doctor make reference to the PCI
prompt list during the consultation? Response options
are ‘Not at all’, ‘A little’, ‘Somewhat’, ‘A great deal’.
Any ‘Not at all’ response will be followed through with
the relevant consultant with a view to resolving the issue
for future clinics conducted.
Fidelity
In the first months of the study a random selection of
clinic consultations will be taped. The additional burden
of taping is an argument for focusing on the set-up
period in order to check how consultants do or do not
use the PCI. The tapes will allow a check on if and how
the PCI print out is being used and it will allow for a
check for contamination in the non-PCI group. It would
be expected that between 3 and 6 months into the study,
two clinics from each consultant would be taped.
Management and governance
The trial will be guided by the Steering Group, meeting
during the set-up and six-monthly thereafter to ensure
progress towards reaching the study’s purpose and to give
oversight regarding research governance. Its’ membership
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includes an independent chairman, at least two other in-
dependent members, the two Unit Lead Investigators,
Trial Coordinator (Full Time), Research Practitioner
(Part-Time), Medical Statistician, Health Economist, IT/
data management representation and a patient representa-
tive from each Unit.
There will be joint-Unit management group meetings
every three months, membership comprising the two
Unit Lead Investigators, dedicated funded researchers,
IT/data management representation and a patient repre-
sentative from each Unit. Statistical and Economic rep-
resentation as required. Within Unit, there will be
monthly Project Team meetings, membership compris-
ing Unit Lead investigator, dedicated funded researchers,
Clinical Trials Nurse(s), and patient representative. Day
to day management issues will be addressed by Unit Re-
searchers and escalate to the Unit Lead Investigator.
Discussion
There is growing evidence that enhanced symptom
monitoring during routine cancer care using patient-
reported outcomes benefits patients in respect to
HRQOL and survival [38]. The premise of this trial is
that the PCI can be integrated into routine clinical con-
sultations with minimal cost implication as the doctor-
patient interaction will be more time efficient and facili-
tate appropriate and targeted multi-professional refer-
rals. The item prompt list approach of the PCI should
have direct benefit for the participants. A key issue limit-
ing successful implementation of patient reported out-
comes in clinical practice is clinicians’ lack of knowledge
on how to effectively utilise PROs data in their clinical
encounters [39]. Hence, for this trial there is an educa-
tional component and training around the use of the
PCI. Also, the patient feedback and analysis of taped
consultations will help underpin the evidence related to
use of the PCI in the consultation. From this material, it
would be possible in the future to develop a more robust
training package, informed from the lessons learnt from
this trial. In addition, the need for clear system guide-
lines built into how to most effectively use the PCI for
the clinician, the patient and other members of the
multi-professional team is recognised [40]. The findings
from this trial will inform the development of a PCI
manual both for patients and professionals.
The collection of the data in both arms of the trial by
touch screen computer-assisted technology (IPAD) has
distinct advantages in terms of data capture. With ad-
vances in digital health it could be expected that this ap-
proach would become regularly employed. Touch screen
health-related QOL data collection can be used for sci-
entific documentation as well as in clinical settings [41].
For the purpose of the trial the computer system has
been transferred from Aintree to the other sites. This
has not been as straightforward as expected. This has
caused delays in the use of the IPADs in the other
clinics. After completion of this trial, in order to support
wider adoption of the PCI approach to patient care, pro-
gress is being made in respect to a cloud based platform
which should be more readily accessible and easier to
use than the current system.
The use of the PCI is a form of intervention in clinic by
the consultant. There are other intervention trials that
focus to improve function and wellbeing in patients with
head and neck cancer. Hansson and colleagues [42] com-
pare a person-centred care intervention in terms of health-
related quality of life, disease-specific symptoms or prob-
lems, with traditional care as a control group for patients
with head and neck cancer. Another trial by van der Hout
and co-workers [43] is testing the efficacy, cost-utility and
reach of an eHealth self-management application ‘Onco-
kompas’ to obtain optimal supportive care. Both trials ex-
plore different tools in a different context to the PCI in this
trial. There are many different ways to help enable patients
to recover from head and neck cancer, and the possibility
of having several evidence based interventions can only
help to improve patient’s outcomes and allow centres to se-
lect the most appropriate intervention with their healthcare
environment. This study has QOL as the primary outcome.
This reflects the importance QOL has in terms of outcome
following HNC. Also, given the inherent difficulties in QOL
evaluation, such as adaptation, response shift, limitations in
questionnaire wording, scaling and scoring, it demonstrates
the potential power of the PCI to impact positively in pa-
tient care. A positive finding from this research will not
only serve to promote wider use of the PCI in HNC, but
also accelerate the development, piloting and introduction
of the PCI in other cancers and chronic conditions. Level 1
evidence as to the benefits of the PCI in HNC care will help
drive up standards of care. This research will add substan-
tially to the evidence supporting the use of question prompt
lists in NHS practice.
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